Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton's jelly-derived mesenchymal stem cells (Navy General Hospital, Beijing)
- Development stage
- Unknown
- Lead developer
- Beike Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intracoronary
01
Overview
This investigational cell therapy consists of allogeneic mesenchymal stem cells derived from the Wharton's jelly of human umbilical cords (WJMSCs). Developed by the Navy General Hospital in Beijing in collaboration with the Shenzhen Beike Cell Engineering Research Institute, the therapy is specifically designed for the treatment of acute myocardial infarction (AMI), including ST-segment elevation myocardial infarction (STEMI). WJMSCs are primitive stromal cells that possess potent immunomodulatory, pro-angiogenic, and anti-inflammatory properties. Upon administration via intracoronary or intravenous infusion, these cells are thought to integrate into ischemic cardiac tissues and secrete paracrine factors that promote tissue regeneration, attenuate adverse ventricular remodeling, and improve overall heart function. The therapy has been evaluated in clinical trials, such as the WANIAMI trial and NCT01291329, to assess its safety and efficacy in the acute phase following reperfusion therapy.
- Other names
- WJMSCsHuman Wharton's jelly-derived mesenchymal stem cellsWJ-MSCs
Beyond the preview
Go deeper on Wharton's jelly-derived mesenchymal stem cells (Navy General Hospital, Beijing).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton's jelly-derived mesenchymal stem cells (Navy General Hospital, Beijing).